Parenteral insulin suppresses T cell proliferation to islet antigens.
The diabetes prevention trial-type 1 (DPT-1) tested whether a combination of SQ and IV insulin therapy would delay the onset of disease in individuals at high risk of progression. We investigated whether this regimen altered T cell responses to human islet proteins using cellular immunoblotting. Among the 10 treated and 7 control subjects studied, we found that there was a significant effect of treatment on cellular immunoblotting responses. We conclude that parenteral insulin may suppress proliferation to islet antigens in individuals at risk for diabetes, but this effect may be transient. Further study is needed to determine whether a therapy that results in sustained suppression of T cell proliferation could yield a measurable clinical benefit.
Greenbaum
Carla J
CJ
Benaroya Research Institute, Seattle, WA, USA. cjgreen@benaroyaresearch.org
McCulloch-Olson
Marli
M
Chiu
Harvey K
HK
Palmer
Jerry P
JP
Brooks-Worrell
Barbara
B
D000293:Adolescent; D000328:Adult; D001323:Autoantibodies / Q000097:blood / Q000276:immunology; D002455:Cell Division / Q000187:drug effects / Q000276:immunology; D002648:Child; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control*; D018450:Disease Progression; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000276:immunology; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage* / Q000276:immunology; D007515:Islets of Langerhans / Q000276:immunology; D010290:Parents; D012307:Risk Factors; D013601:T-Lymphocytes / Q000166:cytology / Q000187:drug effects* / Q000276:immunology; D055815:Young Adult
D001323:Autoantibodies; D007004:Hypoglycemic Agents; D007328:Insulin